3
Announcements
Trials
Browse
Landscape
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
NET
1
Endocrine
1
Conditions
Neoplasms
4
Lung Neoplasms
4
Carcinoma, Non-Small-Cell Lung
3
Breast Neoplasms
3
Lymphoma
2
Head and Neck Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Squamous Cell
2
Brain Neoplasms
2
Adenocarcinoma
2
Urticaria
1
Tuberous Sclerosis
1
Thrombosis
1
Squamous Cell Carcinoma of Head and Neck
1
Smoking
1
Small Cell Lung Carcinoma
1
Severe Combined Immunodeficiency
1
Sarcoma
1
Salivary Gland Neoplasms
1
Renal Insufficiency, Chronic
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Primary Dysautonomias
1
Polycythemia Vera
1
Polycythemia
1
Polycystic Ovary Syndrome
1
Pancreatitis, Chronic
1
Pancreatitis
1
Pancreatic Cyst
1
Ovarian Neoplasms
1
Interventions
lutetium Lu 177 dotatate
29
Everolimus
19
Temozolomide
11
gallium Ga 68 dotatate
10
Nivolumab
10
Magnetic Resonance Spectroscopy
10
Capecitabine
9
pembrolizumab
8
lanreotide
8
Positron Emission Tomography Computed Tomography
8
cabozantinib
7
3-Iodobenzylguanidine
7
177Lu-octreotide, DOTA(0)-Tyr(3)-
7
Somatostatin
6
90Y-octreotide, DOTA-Tyr(3)-
6
telotristat ethyl
5
lenvatinib
5
Octreotide
5
Lutetium-177
5
Ga(III)-DOTATOC
5
Fluorodeoxyglucose F18
5
Carboplatin
5
avelumab
4
Positron-Emission Tomography
4
Ipilimumab
4
Bevacizumab
4
surufatinib
3
pasireotide
3
fluorodopa F 18
3
copper dotatate CU-64
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Neuroendocrine Tumors
×
Phlebotomy
×
Clear all
NCT03130205
2017-08-25
PROGRESS
Uppsala University
Unknown
30 enrolled